New tuberculosis therapy could be more potent than current treatments

New co-treatment could kill cancer cells and suppress tumour growth with fewer side effects

Neem leaves could suppress the development of prostate cancer

New biomarkers and therapeutic targets for prostate cancer

Prostate cancer (lat. Prostate Carcinoma) is the most common cancer and the second leading cause of cancer death in men worldwide. The survival rate for prostate cancer is high if diagnosed early but it falls significantly at advanced stages. An abnormally high level of iron in the body is associated with prostate cancer, and researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) uncovered the mechanism to explain this link. They have found the role of the iron storage gene, FTH1, and its pseudogenes in regulating iron levels in cells and slowing down prostate cancer growth. The new findings could pave the way for future developments in prostate cancer diagnostics and therapeutics.

by
17 days ago

Mangosteens offer hope against tuberculosis

A scientific group at the National University of Singapore (NUS) found that mangosteen, which is a tropical evergreen tree, could be the cure to tuberculosis (lat. Phthisis). Researchers from the NUS Yong Loo Lin School of Medicine (NUS Medicine) has discovered that xanthones, a natural compound with antioxidant and antibacterial properties found in mangosteens, are very effective against common and multidrug-resistant strains of tuberculosis (TB). The study was carried out under the Singapore Programme of Research Investigating New Approaches to Treatment of Tuberculosis (SPRINT-TB), a multiparty programme based at the National University of Singapore.

by
17 days ago

Micro weapon against tuberculosis

The World Health Organization estimates that one-third of the world’s population is infected with TB. Caused by the bacterium Mycobacterium tuberculosis, TB is a virulent disease that spreads from person to person through the air. However, a researchers group from the National University of Singapore (NUS) has developed synthetic antimicrobial peptides which are capable of killing tuberculosis (lat. Phthisis) mycobacteria that cannot be eradicated by standard antibiotics. The research team was led by Associate Professor Rachel Ee from NUS Pharmacy.

by
17 days ago

Blood test could transform tuberculosis diagnosis, help monitor treatment effectiveness

New therapeutic target identified in prostate cancer

New tuberculosis treatment

MRI-based prostate cancer screening that is fast, affordable and pain-free

Today prostate cancer (lat. Prostate Carcinoma) screening is done using a prostate-specific antigen (PSA) blood test, followed by a prostate biopsy if PSA levels are elevated. Research shows that PSA levels are often inaccurate, resulting in overdiagnosis and unnecessary biopsies. Prostate biopsies may have side effects such as bleeding, infection, urinary issues, and erectile dysfunction. A novel approach discovered by two co-founders of Ezra AI company, Emi Gal and Diego Cantor, Ph.D. in Biomedical Engineering, named Ezra which uses MRI scans that are analyzed by expert radiologists to help screen for prostate cancer. Ezra uses MRI scans analyzed by radiologists to detect cancer early. 

by
18 days ago

Molecular breakthrough could halt the spread of prostate cancer

Scientists at the Universities of Bristol, Nottingham and the University of the West of England (UWE Bristol) believe a new treatment, shown to be effective in mice, could halt the growth of tumours in patients with prostate cancer (lat. Prostate Carcinoma). This study shows that a specific compound can inhibit the activity of a molecule which is key to how tumours form new blood vessels. The vessels are essential for the cancer cells to survive and multiply.

by
18 days ago

ClarityDX Prostate - a highly accurate test to predict clinically significant prostate cancer

The lead product of Nanostics, a University of Alberta spin-off company, is ClarityDX Prostate, designed to be a highly accurate test to diagnose clinically significant prostate cancer and is positioned to emerge in the near future as a leading diagnostic tool to bring clarity to the healthcare decisions of prostate cancer. It will help physicians and patients navigate biopsy decision at 2 critical points in care initial diagnosis and active surveillance. ClarityDX Prostate with the guidance of a physician can be used to inform the decision to biopsy and to monitor patients on active surveillance to detect the progression to clinically significant prostate cancer.

by
18 days ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

THE MOST ADVANCED SCIENCE SPINOFF SCOUTING SYSTEM